188 related articles for article (PubMed ID: 2340116)
1. Selective, unilateral cortical infarction increases striatal muscarinic receptor binding: potential evidence for cortical modulation of intrastriatal cholinergic transmission.
Filloux F; Liu TH; Hsu CY; Hunt MA; Wamsley JK
J Chem Neuroanat; 1990; 3(2):125-32. PubMed ID: 2340116
[TBL] [Abstract][Full Text] [Related]
2. Cholinergic innervation and topographical organization of muscarinic binding sites in rat brain: a comparative autoradiographic study.
Tonnaer JA; Ernste BH; Wester J; Kelder K
J Chem Neuroanat; 1988; 1(2):95-110. PubMed ID: 3267343
[TBL] [Abstract][Full Text] [Related]
3. Gallamine binding to muscarinic M1 and M2 receptors, studied by inhibition of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to rat brain membranes.
Burke RE
Mol Pharmacol; 1986 Jul; 30(1):58-68. PubMed ID: 3755217
[TBL] [Abstract][Full Text] [Related]
4. Antibodies to a synthetic peptide can be used to distinguish between muscarinic acetylcholine receptor binding sites in brain and heart.
Luthin GR; Harkness J; Artymyshyn RP; Wolfe BB
Mol Pharmacol; 1988 Sep; 34(3):327-33. PubMed ID: 3419425
[TBL] [Abstract][Full Text] [Related]
5. Regulation of muscarinic receptor subtypes and their responsiveness in rat brain following chronic atropine administration.
Lee W; Wolfe BB
Mol Pharmacol; 1989 Nov; 36(5):749-57. PubMed ID: 2555673
[TBL] [Abstract][Full Text] [Related]
6. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. II. Characterization and regulation of antagonist binding to putative muscarinic subtypes.
Watson M; Roeske WR; Yamamura HI
J Pharmacol Exp Ther; 1986 May; 237(2):419-27. PubMed ID: 3754581
[TBL] [Abstract][Full Text] [Related]
7. Distinct kinetic binding properties of N-[3H]-methylscopolamine afford differential labeling and localization of M1, M2, and M3 muscarinic receptor subtypes in primate brain.
Flynn DD; Mash DC
Synapse; 1993 Aug; 14(4):283-96. PubMed ID: 8248852
[TBL] [Abstract][Full Text] [Related]
8. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. I. Characterization and regulation of agonist binding to putative muscarinic subtypes.
Watson M; Yamamura HI; Roeske WR
J Pharmacol Exp Ther; 1986 May; 237(2):411-8. PubMed ID: 3754580
[TBL] [Abstract][Full Text] [Related]
9. [3H]Pirenzepine and [3H]quinuclidinyl benzilate binding to brain muscarinic cholinergic receptors. Differences in measured receptor density are not explained by differences in receptor isomerization.
Luthin GR; Wolfe BB
Mol Pharmacol; 1984 Sep; 26(2):164-9. PubMed ID: 6548291
[TBL] [Abstract][Full Text] [Related]
10. Effects of in vivo and in vitro treatments with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on putative muscarinic receptor subtypes in rat brain.
Norman AB; Creese I
Mol Pharmacol; 1986 Aug; 30(2):96-103. PubMed ID: 3755499
[TBL] [Abstract][Full Text] [Related]
11. Comparison of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to muscarinic cholinergic receptors in rat brain.
Luthin GR; Wolfe BB
J Pharmacol Exp Ther; 1984 Mar; 228(3):648-55. PubMed ID: 6546770
[TBL] [Abstract][Full Text] [Related]
12. Characterization of [3H]pirenzepine binding to muscarinic cholinergic receptors solubilized from rat brain.
Luthin GR; Wolfe BB
J Pharmacol Exp Ther; 1985 Jul; 234(1):37-44. PubMed ID: 3839265
[TBL] [Abstract][Full Text] [Related]
13. Receptor alterations in subcortical structures after bilateral middle cerebral artery infarction of the cerebral cortex.
Dawson VL; Hsu CY; Liu TH; Dawson TM; Wamsley JK
Exp Neurol; 1994 Jul; 128(1):88-96. PubMed ID: 8070526
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of muscarinic receptors in the rat caudate-putamen after lesioning of the ipsilateral nigrostriatal dopamine pathway with 6-hydroxydopamine (6-OHDA): normalization by fetal mesencephalic transplants.
Dawson TM; Dawson VL; Gage FH; Fisher LJ; Hunt MA; Wamsley JK
Brain Res; 1991 Feb; 540(1-2):145-52. PubMed ID: 1905173
[TBL] [Abstract][Full Text] [Related]
15. Muscarinic cholinergic receptor binding sites differentiated by their affinity for pirenzepine do not interconvert.
Gil DW; Wolfe BB
J Pharmacol Exp Ther; 1986 May; 237(2):577-82. PubMed ID: 3009794
[TBL] [Abstract][Full Text] [Related]
16. Differential ontogeny of putative M1 and M2 muscarinic receptor binding sites in the murine cerebral cortex and heart.
Evans RA; Watson M; Yamamura HI; Roeske WR
J Pharmacol Exp Ther; 1985 Dec; 235(3):612-8. PubMed ID: 3841156
[TBL] [Abstract][Full Text] [Related]
17. Effect of unilateral perinatal hypoxic-ischemic brain injury in the rat on striatal muscarinic cholinergic receptors and high-affinity choline uptake sites: a quantitative autoradiographic study.
Kostic V; Przedborski S; Jackson-Lewis V; Cadet JL; Burke RE
J Neurochem; 1991 Dec; 57(6):1962-70. PubMed ID: 1940912
[TBL] [Abstract][Full Text] [Related]
18. Characterization of high affinity [3H]pirenzepine and (-)-[3H] quinuclidinyl benzilate binding to muscarinic cholinergic receptors in rabbit peripheral lung.
Bloom JW; Halonen M; Lawrence LJ; Rould E; Seaver NA; Yamamura HI
J Pharmacol Exp Ther; 1987 Jan; 240(1):51-8. PubMed ID: 3806397
[TBL] [Abstract][Full Text] [Related]
19. Muscarinic and dopaminergic receptor subtypes on striatal cholinergic interneurons.
Dawson VL; Dawson TM; Wamsley JK
Brain Res Bull; 1990 Dec; 25(6):903-12. PubMed ID: 2149667
[TBL] [Abstract][Full Text] [Related]
20. Multiple in vitro interactions with and differential in vivo regulation of muscarinic receptor subtypes by tetrahydroaminoacridine.
Flynn DD; Mash DC
J Pharmacol Exp Ther; 1989 Aug; 250(2):573-81. PubMed ID: 2760841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
